Literature DB >> 1335026

The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker.

M Etienne-Julan1, P Roux, S Carillo, P Jeanteur, M Piechaczyk.   

Abstract

Using streptavidin-bound antibodies specific for both viral and cell membrane epitopes, we have reported previously that human cells may be infected by murine ecotropic retroviruses through an interaction with major histocompatibility complex class I and class II antigens, and thus have demonstrated that cell targeting by recombinant retroviruses is feasible. We report here that (i) growth factor or hormone receptors, such as those for epidermal growth factor (EGF) and insulin, can also mediate infection of human cells; (ii) a biotinylated cytokine or hormone can substitute for the anti-cell antibody in bispecific antibody complexes, thus extending the versatility of the method; (iii) although yields are low in our assay, infection efficiency clearly appears to depend upon the biochemical composition of molecular bridges because bi-functional antibody complexes are more efficient than cytokine-antibody complexes in the case of the EGF receptor. Finally, our study indicates that different cell membrane molecules are not equally efficient in allowing infection of human cells because targeting of the transferrin, high density lipoprotein and galactose receptors, as well as that of various membrane glycoconjugates, by murine ecotropic retroviruses did not lead to the establishment of a proviral state.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335026     DOI: 10.1099/0022-1317-73-12-3251

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  17 in total

1.  Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types.

Authors:  A L Boerger; S Snitkovsky; J A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Redirecting retroviral tropism by insertion of short, nondisruptive peptide ligands into envelope.

Authors:  Timothy J Gollan; Michael R Green
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 3.  Retroviral vectors. From laboratory tools to molecular medicine.

Authors:  R G Vile; A Tuszynski; S Castleden
Journal:  Mol Biotechnol       Date:  1996-04       Impact factor: 2.695

Review 4.  Development of retroviral vectors as safe, targeted gene delivery systems.

Authors:  W H Günzburg; B Salmons
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

5.  Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins.

Authors:  M Marin; D Noël; S Valsesia-Wittman; F Brockly; M Etienne-Julan; S Russell; F L Cosset; M Piechaczyk
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  Retroviral retargeting by envelopes expressing an N-terminal binding domain.

Authors:  F L Cosset; F J Morling; Y Takeuchi; R A Weiss; M K Collins; S J Russell
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

7.  Receptor-binding properties of a purified fragment of the 4070A amphotropic murine leukemia virus envelope glycoprotein.

Authors:  J L Battini; P Rodrigues; R Müller; O Danos; J M Heard
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

8.  Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors.

Authors:  S Valsesia-Wittmann; A Drynda; G Deléage; M Aumailley; J M Heard; O Danos; G Verdier; F L Cosset
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein.

Authors:  S Snitkovsky; J A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

10.  Mutation of amino acids within the gibbon ape leukemia virus (GALV) receptor differentially affects feline leukemia virus subgroup B, simian sarcoma-associated virus, and GALV infections.

Authors:  C S Tailor; Y Takeuchi; B O'Hara; S V Johann; R A Weiss; M K Collins
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.